Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): Current Perspectives

Despite the availability of global and regional guidelines to curtail the adverse clinical outcomes associated with chronic kidney disease-mineral and bone disorder (CKD-MBD), most CKD patients are still affected by the consequences of abnormalities of CKD-MBD. This important clinical complication o...

Full description

Saved in:
Bibliographic Details
Published in:International journal of nephrology and renovascular disease Vol. 12; pp. 263 - 276
Main Authors: Waziri, Bala, Duarte, Raquel, Naicker, Saraladevi
Format: Journal Article
Language:English
Published: New Zealand Dove Medical Press Limited 01.12.2019
Taylor & Francis Ltd
Dove
Dove Medical Press
Subjects:
Aluminum
Biological markers
Bone diseases
Calcification
Calcium phosphates
chronic kidney disease-mineral and bone disorder
Chronic kidney failure
Clinical trials
Drinking water
emerging trends
Endocrine system
Fibroblast growth factor 23
Fibroblast growth factors
Fibroblasts
Fractures
Growth factors
Hemodialysis
Hormones
Hypotheses
Kidney diseases
management
Metabolism
Minerals
Parathyroid
Parathyroid hormone
Parathyroid hormones
Pathogenesis
Phosphate binders
Phosphates
Review
updated pathogenesis
Vitamin D
updated pathogenesis
management
emerging trends
chronic kidney disease–mineral and bone disorder
ISSN:1178-7058, 1178-7058
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the availability of global and regional guidelines to curtail the adverse clinical outcomes associated with chronic kidney disease-mineral and bone disorder (CKD-MBD), most CKD patients are still affected by the consequences of abnormalities of CKD-MBD. This important clinical complication of CKD continues to be studied, in order to improve the understanding and management of CKD-MBD. Some notable discoveries include the role of fibroblast growth factor 23 (FGF23) in the pathogenesis of CKD-MBD, leading to a shift from the previous well-established classic trade-off hypothesis to the updated trade-off hypothesis. More recently, there has been a shift from the treatment of CKD-MBD based on a single level of biomarkers to serial measurements of calcium, phosphate and parathyroid hormone (PTH). Furthermore, some clinical trials have emerged after the 2009 Kidney Disease-Improving Global Outcomes (KDIGO) Guidelines, leading to the 2017 KDIGO updated recommendations. Hence, this review gives an overview of the rapidly evolving trends in CKD-MBD, linking the past and current concepts of CKD-MBD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1178-7058
1178-7058
DOI:10.2147/IJNRD.S191156